Researchers at The Sciensano Institute in Belgium will be using urine collected through Colli-Pee ® to understand Chlamydia presence in all ages and genders in the Belgium population.
Novosanis has been co-awarded a CASUS grant, which allows to build a next-generation Colli-Pee ® that will be used in a molecular screening solution for cervical cancer.
Novosanis receives grant from Interreg CrossCare to build a next-generation of its unique and patented intradermal drug delivery device, VAX-ID, in collaboration with living labs Happy...
A wrap to an exciting and eventful week! Our Product designer, Alejandra Ríos Cortés, represented Novosanis at the Royal Mission, an initiative led by Princess Astrid of Belgium, to boost...
Today, 4 February, is #worldcancerday. Cervical cancer is one of the most preventable forms of cancer if it’s detected early. HPV urine testing can offer a solution for screening next to...
Timothi Van Mulder will present Novosanis' breakthrough results on the development of a painless injection device for children at 12 th Vaccine Congress in Budapest, Hungary from September...
The Summer Edition of our NewsTalks is live! Read updates on VAX-ID, urine as a sample for detection of breast cancer and the live testing of our next generation Colli-Pee suited for home-...
Novosanis attended IUSTI2018 from June 26 to June 30 in Dublin, Ireland. Our Colli-Pee device suited for first-void urine collection allowing for improved detection of STIs was on display...
Novosanis
